Clinical Trial Search

Primary: Number of Participants With Any Adverse Events (AEs) and Serious AEs (SAEs) — 120; 27 Participants

Primary: Change in Flow Mediated Dilation — 0.26; -1.5 percentage of flow mediated dilation

Primary: Death or Hospitalization, Whichever Occurs First — 34.2; 36.4 Composite events/100 person-years — p=0.52

Primary: Self-reported Intake of Fruit and Vegetables (Number of Portions Per Day); — 1.9; 6.1 Portions per day

Primary: Flow-Mediated Dilation (FMD) — 3.1; 6.7; 4.7; 6.9 percentage of change in FMD — p=<0.05

Primary: Time Spent in Physical Activity as Measured by Upright Time (Minutes Per Day) Monitored by ActivPal Monitor — 278; 269; 293; 285 minutes per day

Primary: Spirometry Measurement: Percentage of Predicted Forced Expiratory Volume in 1 Second (FEV1 %Pred) — 75.572; 100.837; 108.311; 111.849 percent of predicted FEV1 — p=<0.0001

Primary: Forced Expiratory Volume in the First Second (FEV1) — 54; 54 Percentage predicted — p=0.09

Primary: Baseline Resting Cardiac Index (CI) — 2.4; 2.36 L/min/m^2 — p=0.85

Primary: Number of Participants With Accurate Classification of Irreversible Airflow Obstruction — 10; 5 Participants

Primary: Forced Expiratory Volume in One Second (FEV1), Peak Effect Within 0 - 24 Hours Post-dose — 1.71; 1.79; 1.72; 1.71 L

Primary: Number of Participants Who Received COPD Prescription for Maintenance Treatment at Baseline — 735; 68; 554; 105 Participants

Primary: ANALYSIS OF LUNG DEPOSITION - Penetration Index — 0.8; 0.72; 0.69; 0.58 ratio

Primary: 6 Minute Walk Distance — 458.2; 466.1 meters

Primary: Hospital Readmission — 1.12; 1.7 hospital readmissions

Primary: Participants Who Experienced Safety Concerns, Where Safety Concerns of Quercetin Supplementation is Indicated by Significant Change From Baseline Measures of Tests…

Primary: Mean Change From Baseline in Peak FEV1 (Over 3 Hours) at Week 4 — 0.203; 0.209; 0.257; 0.196 Liters — p=<0.001

Primary: COPD Diagnosis — 39 participants

Primary: Change in 6 Minute Walk Test — 7.00; 16.60; 16.00; 4.90 Meters walked in 6 minutes

Primary: Age of the Chronic Obstructive Pulmonary Disease (COPD) Patients at the Time of COPD Diagnosis - US — 65.6; 64.4 Years

Primary: Safety of Doxycycline, as Measured by the Number of Subjects With Any Treatment-related Adverse Events. — 3; 1 Participants

Primary: Annualized Incidence Rate of Moderate or Severe Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD) — 0.92; 0.95 AECOPD events/person-year — p=0.941

Primary: Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) — 1.61; 1.58; 1.62; 1.62 Liter

Primary: Number of Participants Who Prioritized Healthcare Topics — 90; 79; 23; 22 participants — p=.91

Primary: Percentage of Participants Whose Post-albuterol Forced Expiratory Volume in One Second (FEV1) Was <80% Predicted Normal — 70; 30 percentage of participants

Primary: Pulmonary Microvascular Blood Volume, CV — 0.89; 0.88; 0.92; 0.91 CV — p=0.84

Primary: Percentage of Participants With COPD Who Rate the Use of the ELLIPTA Inhaler as Easy or Very Easy, Among Those Who Demonstrate Correct Use of the Inhaler at the End of…

Primary: Levels of PGP From Sputum Samples of COPD Patients Being Treated With Azithromycin. — 2.27; 5.15 ng/mL — p=0.045

Primary: Mean Number of Chronic Obstructive Pulmonary Disease (COPD)-Related Hospitalizations and Emergency Department (ED) Visits Per Patient Within Each Study Arm — 0.72; 1.40…

Primary: 8-isoprostane Levels as Biochemical Markers for Nonenzymatic Oxidative Stress in Asthma — 292.4; 421.8 pg/ml